Immunome (NASDAQ:IMNM) and CohBar (NASDAQ:CWBR) Financial Contrast

Immunome (NASDAQ:IMNM) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Immunome and CohBar, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	0	0	7	0	3.00
CohBar	0	0	0	0	0.00

Immunome currently has a consensus target price of $28.83, suggesting a potential upside of 158.59%. Given Immunome’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunome is more favorable than CohBar.

Institutional & Insider Ownership

44.6% of Immunome shares are owned by institutional investors. Comparatively, 2.5% of CohBar shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Comparatively, 6.5% of CohBar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Immunome has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.

Profitability

This table compares Immunome and CohBar’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	-3,014.59%	-48.63%	-41.62%
CohBar	N/A	N/A	N/A

Earnings and Valuation

This table compares Immunome and CohBar”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$14.02 million	49.64	-$106.81 million	($8.11)	-1.37
CohBar	N/A	N/A	-$12.18 million	N/A	N/A

CohBar has lower revenue, but higher earnings than Immunome.

Summary

Immunome beats CohBar on 7 of the 11 factors compared between the two stocks.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

About CohBar

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.